StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical ...

Here the authors show the structures of single-pass transmembrane receptor guanylyl cyclase in both apo and hormone-bound states, advancing our understanding of cross-membrane signaling by single ...

The risk for emergently treated hypocalcemia in individuals receiving denosumab peaked at 2 weeks after administration and ...

The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

The air pollutants are more than just a respiratory hazard; they also interfere with bone density and mineral composition ...

Wells Fargo analyst Derek Archila initiated coverage of Septerna (SEPN) with an Overweight rating and $43 price target The firm believes there ...

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

Another asset, MBX 1416 targeting Post-Bariatric Hypoglycemia [PBH], is in a phase 1 trial. Other candidates are preclinical. Lead asset MBX 2109 is a parathyroid hormone peptide prodrug. A prodrug, ...

A Gastroenterologist at Ohio State Wexner Medical Center on Thursday refuted an inaccurate claim made by the Chief Minister ...

They produce parathyroid hormone (PTH), which helps maintain the balance of calcium essential for various bodily functions, like your nervous system and muscle function. When calcium levels drop, ...